Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 27gb4 | — |
patient was inadvertently given an extra dose of Flulaval today; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 12-month-old male patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (batch number 27gb4, expiry date 30-JUN-2025) for prophylaxis. Concomitant products included INFLUENZA VACCINE INACT SPLIT 3V (FLULAVAL) and INFLUENZA VACCINE INACT SPLIT 3V (FLULAVAL). On 11-FEB-2025, the patient received the 3rd dose of FluLaval 2024-2025 season. On 11-FEB-2025, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced extra dose administered (Verbatim: patient was inadvertently given an extra dose of Flulaval today). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-FEB-2025 The nurse stated that a patient was inadvertently given an extra dose of Flulaval on the date of reporting, which led to extra dose administered. The patient was indicated for two doses, but the second dose was not captured in the electronic medical record (EMR). Thus, when the patient was at his well-child check on the day of reporting, the system showed he was due for a dose of FluLaval. The dose was given, and then afterward the parent pointed out the patient had already been given the second dose.
FLULAVAL; FLULAVAL